Retatrutide

CagriSema and retatrutide represent two fundamentally different approaches to next-generation obesity treatment. CagriSema combines two proven mechanisms (amylin + GLP-1) in a fixed-dose injection, achieving 20.4% weight loss in Phase 3, with an NDA already filed and the advantage of building on the well-characterized semaglutide platform. Retatrutide's novel triple-agonist approach produced 28.7% weight loss in Phase 3 TRIUMPH-4 (confirming 24.2% in Phase 2) by adding glucagon and GIP receptor activation. CagriSema is likely to reach market sooner, but retatrutide offers the greatest peak efficacy of any single anti-obesity agent.

Retatrutide holds a clear advantage in both efficacy and development timeline. Its triple-receptor mechanism produced 28.7% weight loss in Phase 3 -- substantially greater than CT-388's 22.5% in Phase 2 -- and it is approximately 2-3 years ahead in the regulatory pathway. However, this superior efficacy comes at a cost: higher GI side effect rates and a novel dysesthesia safety signal. CT-388's signaling-biased approach offers a potentially better-tolerated dual agonist with impressive Phase 2 results and no plateau at 48 weeks. For patients who cannot tolerate triple agonist side effects, CT-388 may eventually represent a compelling alternative. Both remain investigational and are not available outside clinical trials.

Retatrutide achieved greater peak weight loss (28.7% at 68 weeks in Phase 3 TRIUMPH-4; 24.2% at 48 weeks in Phase 2) compared to mazdutide's Phase 3 results (20.1% at 60 weeks), likely due to its additional GIP receptor agonism. However, mazdutide is significantly further along in clinical development, with multiple completed Phase 3 trials, regulatory approval in China for T2D, and a head-to-head Phase 3 win over semaglutide. Mazdutide's development is primarily focused on Chinese populations, while retatrutide targets global markets. Both represent meaningful advances over single-target GLP-1 agonists.

Semaglutide is the established gold standard with FDA approval, proven cardiovascular benefit, extensive clinical data, and multiple formulation options. Retatrutide's triple agonism shows promise for greater weight loss and liver fat reduction, but remains investigational with Phase 2 data only. Phase 3 results will determine whether retatrutide's early advantages translate into meaningful clinical superiority.

Retatrutide demonstrated greater weight loss than survodutide in their respective Phase 2 trials (24.2% vs 18.7%), likely driven by its unique triple-agonist mechanism that adds GIP receptor activation. However, survodutide is further along in clinical development with Phase 3 trials fully enrolled and FDA Breakthrough Therapy Designation for MASH, where it has shown strong efficacy. Both represent significant advances beyond single-target GLP-1 agonists. The choice between them may ultimately depend on clinical indication: retatrutide for maximum weight loss and metabolic improvement, survodutide for MASH-focused treatment where it has the most advanced regulatory pathway.

Tirzepatide is the proven choice with FDA approval and extensive clinical data; Retatrutide shows potential for greater efficacy through triple-agonism but awaits Phase 3 results